News

Categories

August 1, 2024

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

August 1, 2024

Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results

July 30, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

July 25, 2024

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

July 22, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

July 11, 2024

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

June 17, 2024

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

June 10, 2024

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

May 29, 2024

Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer

May 29, 2024

Introducing Pride in Biotech

May 28, 2024

Zymeworks Announces Participation in Upcoming Investor Conferences

May 2, 2024

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results